Clinical Research Directory
Browse clinical research sites, groups, and studies.
Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
Sponsor: National University Hospital, Singapore
Summary
This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.
Official title: A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals
Key Details
Gender
All
Age Range
21 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2024-11-01
Completion Date
2028-12-31
Last Updated
2026-01-22
Healthy Volunteers
Yes
Interventions
Liquid Biopsy (SPOT-MAS Assay)
Blood-based genome-wide DNA methylation assay performed on plasma samples to detect tumor-associated methylation patterns suggestive of lung cancer.
Exosome-Based Liquid Biopsy Assay
Blood-based assay analyzing exosome-associated biomarkers to support early detection of lung cancer.
Low-Dose CT Thorax (LDCT)
Low-dose computed tomography of the thorax performed for lung cancer screening
Locations (1)
National University Hospital Singapore
Singapore, Singapore